(NASDAQ: SLN) Silence Therapeutics's forecast annual revenue growth rate of 2.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.57%.
Silence Therapeutics's revenue in 2023 is $35,051,250.On average, 4 Wall Street analysts forecast SLN's revenue for 2023 to be $3,846,304,521, with the lowest SLN revenue forecast at $2,442,006,037, and the highest SLN revenue forecast at $5,522,065,909. On average, 3 Wall Street analysts forecast SLN's revenue for 2024 to be $3,159,294,557, with the lowest SLN revenue forecast at $2,882,843,232, and the highest SLN revenue forecast at $3,654,308,322.
In 2025, SLN is forecast to generate $4,812,086,006 in revenue, with the lowest revenue forecast at $1,773,789,659 and the highest revenue forecast at $9,779,625,128.